Giulia C. Kennedy, Ph.D.
Chief Scientific Officer and SVP of Research and Development
Giulia C. Kennedy is Chief Scientific Officer and Senior Vice President of Research, Product and Clinical Development for Veracyte. Since joining the genomic diagnostics company in 2008, Dr. Kennedy has overseen the development of three commercialized genomic tests that help reduce unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty. The company’s tests are setting new standards in disease diagnosis, where they are changing patient care and obtaining insurance coverage. Through Dr. Kennedy’s scientific leadership, Veracyte continually pushes the boundaries of what is possible in genomic diagnostics, using big data and machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc.
Before that, she was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development. Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes. She holds a Ph.D. degree in biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 50 articles in peer-reviewed scientific journals and is a co-inventor on more than 20 patents.